Industry

An AI-powered opportunistic screening tool is being developed to identify patients with undiagnosed aortic stenosis using existing imaging data. The technology aims to detect asymptomatic or unrecognized cases by analyzing routine medical scans that were performed for other clinical indications.

Digest: Early detection of aortic stenosis through opportunistic AI screening could identify intervention candidates before symptom onset, potentially improving outcomes and expanding the patient pool for TAVR and SAVR procedures.

Banner Health is partnering with physicians to expand cardiovascular procedures in ambulatory surgery centers. The initiative aims to shift appropriate heart procedures from hospital-based settings to lower-cost ASC environments.

Digest: ASC migration of structural heart procedures could impact reimbursement models and site-of-service strategies as health systems seek cost reduction while maintaining quality outcomes.

Ventripoint Diagnostics is expanding subscription-based access to its FDA-cleared VMS+ 4.0 platform, which uses AI and Knowledge Based Reconstruction technology to generate MRI-comparable 3D volumetric measurements of all four cardiac chambers from standard echocardiographic images. The company is implementing a Device-as-a-Service model targeting approximately 80% subscription-based adoption to reduce capital budget barriers for hospital implementation.

Digest: This AI-powered echocardiographic platform addresses a critical need for accurate right ventricular volumetric assessment without requiring MRI, with subscription pricing potentially lowering adoption barriers for structural heart programs evaluating patients for interventions.

ASCEND Cardiovascular and Epsilon Imaging announced a strategic partnership integrating ASCEND's enterprise structured reporting platform with Epsilon's EchoInsight Zero Footprint advanced echo analysis system featuring speckle-tracking strain imaging. The integrated solution uses AI-based view classification and bidirectional data exchange to automate strain measurement workflow, generating over 100 standardized measurements based on ASE chamber quantification guidelines without manual data entry.

Digest: Automated strain imaging integration addresses a key workflow barrier to routine use of global longitudinal strain for cardiotoxicity monitoring, heart failure assessment, and valvular disease management in structural heart programs.

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

Economic analysis suggests early transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis may be cost-effective compared to watchful waiting. The cost savings would accrue from preventing heart failure hospitalizations and complications associated with delayed intervention.

Digest: This health economics data could influence coverage decisions and clinical practice patterns by supporting intervention before symptom onset in severe AS patients.

New data from the PARTNER 3 trial demonstrate early clinical benefits of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in low-risk patients. The updated analysis reinforces TAVR's favorable early outcomes in this patient population.

Digest: These findings support expanding TAVR utilization in low-risk surgical candidates and may influence treatment algorithms and guideline recommendations for aortic stenosis management.

The U.S. Department of Justice charged 455 defendants, including 90 physicians and licensed healthcare professionals, with over $6.5 billion in alleged Medicare and Medicaid fraud in a 2026 national enforcement sweep. Healthcare law experts emphasize the need to distinguish between intentional fraud and honest billing mistakes resulting from complex regulatory requirements, as federal investigations continue with CMS deferring over $1 billion in Medicaid payments pending documentation review.

Digest: Heightened federal fraud enforcement and compliance scrutiny may impact structural heart practices through increased billing audits, reimbursement delays, and pressure to document medical necessity for high-cost procedures like TAVR and mitral interventions.

Abbott has initiated the Treat TR study, a post-market study enrolling approximately 1,000 patients across up to 100 sites in the U.S., Canada, and Europe to evaluate the safety and performance of the TriClip transcatheter edge-to-edge repair system for tricuspid regurgitation in real-world settings. Patients will be followed for five years, with a sub-study examining the system's potential to reverse cardiac remodeling.

Digest: This large-scale real-world evidence study will provide critical post-market performance data for TriClip TEER, informing adoption decisions and potentially expanding treatment paradigms for TR in clinical practice.

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

HOPPR launched its fifth AI foundation model, the EF Chest CT Narrative Model, which processes 3D chest CT volumes to generate narrative reports across pulmonary, mediastinal, cardiac, upper abdominal, osseous, and soft tissue regions. The model was trained on a large proprietary U.S. dataset with deliberate overrepresentation of serious conditions including aortic injury, pulmonary embolism, rib fractures, and pneumothorax.

Digest: This AI model offers potential automated assessment of cardiac and aortic anatomy on chest CT, which could support preprocedural planning and screening for structural heart interventions, though clinical validation data were not provided.

ElectroWire Medical received FDA 510(k) clearance for the LightningWire Transseptal Puncture System, a novel electrosurgical guidewire designed to create atrial septal defects for left-sided cardiac procedures. The 0.032-inch diameter system features proprietary insulation enabling low-power transseptal puncture while providing stiffness comparable to 0.035-inch guidewires, with compatibility across existing electrosurgical generators and transseptal introducers.

Digest: This device addresses a critical access step for multiple structural heart procedures including TMVR, LAAO, and atrial fibrillation ablation, potentially improving procedural efficiency and reducing costs through platform-agnostic compatibility.

A new study examines failure to rescue rates following transcatheter aortic valve replacement (TAVR) procedures, comparing outcomes between high-volume and low-volume hospital centers. The analysis focuses on hospital-level differences in mortality following post-procedural complications.

Digest: Failure to rescue metrics may inform hospital volume-outcome relationships and quality benchmarking for TAVR programs, with implications for center credentialing and patient referral patterns.

Medical societies are publicly responding to a CMS proposal regarding TAVR coverage as the agency approaches its final decision. The societies' positions indicate stakeholder engagement on potential changes to reimbursement or coverage criteria for transcatheter aortic valve replacement.

Digest: CMS coverage decisions directly impact patient access to TAVR and procedural volumes at structural heart programs, particularly if eligibility criteria or site-of-service requirements change.

Medtronic has issued a recall of a heart valve delivery system due to an identified safety risk. Specific details regarding the affected device model, nature of the safety concern, patient impact, and scope of the recall were not provided in the available content.

Digest: Device recalls can impact procedural planning and inventory management for structural heart programs, and may signal potential adverse events requiring vigilance in patients who received the affected system.

Transcatheter aortic valve replacement using an Edwards Lifesciences valve system demonstrated encouraging outcomes in patients with severe aortic regurgitation. The data suggest TAVR may be a viable treatment option for this traditionally surgical patient population.

Digest: Severe AR has been a relative contraindication for TAVR due to anatomical challenges, and positive data could expand the treatment population and market for Edwards' valve technology.

A high-intensity ultrasound technology designed to treat calcified valve leaflets has launched in Europe. No specific clinical data or device details were provided in the article content.

Digest: Novel leaflet modification technologies could expand treatment options for calcified valves, though clinical validation data are needed to assess utility in structural heart interventions.

CMS proposed significant policy changes affecting TAVR reimbursement and coverage, prompting responses from interventional cardiologists and cardiac surgeons. The clinical and financial implications of these proposed modifications are being evaluated by the structural heart community.

Digest: CMS reimbursement policy directly impacts TAVR program sustainability, patient access, and the economic viability of structural heart programs nationwide.

CMS has proposed expanding Medicare coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic patients with severe aortic stenosis. This represents a significant policy shift from current coverage criteria that require symptomatic presentation.

Digest: Expansion of Medicare coverage to asymptomatic severe AS patients could substantially increase the eligible TAVR population and accelerate treatment timing, potentially preventing symptom development and improving outcomes.

The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).

Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.

A study demonstrates that redo transcatheter aortic valve replacement using balloon-expandable valves is associated with favorable clinical outcomes and key procedural improvements. The findings support the safety and efficacy of repeat TAVR procedures in patients with failed bioprosthetic valves.

Digest: As the TAVR population ages and device durability becomes critical, establishing safety profiles for redo TAVR with specific valve platforms helps guide treatment decisions for structural valve degeneration.

TAVR valve implant depth significantly influences post-procedural outcomes including paravalvular leak, conduction abnormalities requiring permanent pacemaker, and coronary obstruction risk. Optimal implantation depth varies by valve platform, with higher implantation generally associated with reduced paravalvular regurgitation but increased pacemaker rates, while deeper implantation may increase coronary occlusion risk particularly in valve-in-valve procedures.

Digest: Precise implant depth optimization is a modifiable procedural factor that directly impacts major TAVR complications and may influence valve selection and procedural planning across risk stratifications.

An advocacy group is calling on the Trump administration to change regulations or policies affecting transcatheter aortic valve replacement (TAVR) access, framing the issue as government interference in clinical decision-making. No specific policy changes, clinical data, or patient access barriers are detailed in the available content.

Digest: Potential regulatory or reimbursement policy changes could significantly impact TAVR utilization patterns and patient access, though the specific issues being advocated remain unclear from this brief report.

Three-year follow-up data from the SMART trial continues to demonstrate superior structural valve deterioration outcomes for self-expanding TAVR valves compared to balloon-expandable systems. The durability advantage of self-expanding valves persisted at the 3-year time point.

Digest: This extends evidence supporting differential long-term durability between TAVR platform designs, which is critical for valve selection decisions particularly in younger, lower-risk patients where long-term performance drives clinical and economic outcomes.

Boston Scientific invested $1.5 billion in MiRus with an option to acquire its transcatheter aortic valve replacement (TAVR) business. The strategic investment provides Boston Scientific access to MiRus's TAVR platform and optionality in the structural heart valve market.

Digest: This major investment signals Boston Scientific's intent to enter or expand in the TAVR market, potentially reshaping competitive dynamics currently dominated by Edwards and Medtronic.

A photo gallery showcases cardiac surgery technologies exhibited at the 106th Annual Meeting of the American Association for Thoracic Surgery (AATS). The gallery provides visual documentation of the latest surgical devices and innovations presented at this major cardiac surgery conference.

Digest: Visual documentation of emerging surgical technologies at AATS helps structural heart professionals identify innovation trends and evaluate new devices that may impact surgical practice and compete with transcatheter approaches.

Edwards Lifesciences' Resilia tissue, an integrity preservation technology for bioprosthetic heart valves, demonstrates favorable long-term durability outcomes. The tissue treatment is designed to reduce calcium buildup and improve structural valve deterioration resistance compared to conventional tissue.

Digest: Long-term durability data for Resilia tissue is critical for structural heart professionals evaluating valve choice in younger, lower-risk patients where extended valve longevity directly impacts reintervention rates and lifetime management strategies.

A study comparing outcomes of redo TAVR procedures found no significant differences between supra-annular and intra-annular valve designs. The findings suggest that valve positioning strategy does not substantially impact clinical outcomes in patients requiring repeat transcatheter aortic valve replacement.

Digest: This evidence supports flexibility in valve selection for redo TAVR procedures, potentially influencing procedural planning and device choice in the growing population of patients with failed bioprosthetic valves.

The FDA has approved Medtronic's next-generation mitral valve system for commercial use in the United States. Specific device details, indication, and pivotal trial data supporting the approval were not provided in the article.

Digest: FDA approval of a new mitral valve platform from a major manufacturer expands the structural heart toolset for treating mitral regurgitation and impacts competitive landscape in the rapidly evolving TMVR market.

The American Heart Association awarded $15 million to three research centers (Mass General Brigham, Cincinnati Children's Hospital, and University of Pittsburgh) to establish a Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease. The four-year initiative addresses a growing global health burden affecting over 80 million people worldwide and contributing to more than 57,000 deaths annually in the U.S.

Digest: This dedicated funding network may accelerate discovery of biomarkers and diagnostic tools for pre-symptomatic valve disease detection, potentially expanding the treatable patient population before irreversible cardiac remodeling occurs.